Washington Administrative Code › Title 246 - Health, Department of › FACILITY STANDARDS AND LICENSING › Chapter 246-341 - Behavioral health agency licensing and certification requirements › CERTIFICATION STANDARDS FOR OPIOID TREATMENT PROGRAMS (OTP) › Section 246-341-1000 - Opioid treatment programs (OTP)-General

Current through Register Vol. 24-14, July 15, 2024
(1) Opioid treatment programs (OTP) may
				  order, possess, dispense, and administer medications approved by the United
				  States Food and Drug Administration for the treatment of opioid use disorder,
				  alcohol use disorder, tobacco use disorder, and reversal of opioid overdose.
				  OTP services include withdrawal management and maintenance treatment along with
				  evidence-based therapy.
(2) An
				  agency providing opioid treatment program services must ensure that the
				  agency's individual record system complies with all federal and state reporting
				  requirements relevant to opioid drugs approved for use in treatment of opioid
				  use disorder, alcohol use disorder, tobacco use disorder, and reversal of
				  opioid overdose.
(3) An agency
				  must:
(a) Use evidence-based therapy in
				  addition to medication in the treatment program;
(b) Identify individual mental health needs
				  during assessment process and refer them to appropriate treatment if not
				  available on-site;
(c) Provide
				  education to each individual admitted, totaling no more than fifty percent of
				  treatment services, on:
(i) Alcohol, other
				  drugs, and substance use disorder;
(ii) Relapse prevention;
(iii) Infectious diseases including human
				  immunodeficiency virus (HIV) and hepatitis A, B, and C;
(iv) Sexually transmitted infections;
				  and
(v) Tuberculosis
				  (TB);
(d) Provide
				  information to each individual on:
(i)
				  Emotional, physical, and sexual abuse;
(ii) Nicotine use disorder;
(iii) The impact of substance use during
				  pregnancy, risks to the developing fetus before prescribing any medications to
				  treat opioid use disorder, the risks to both the expecting parent and fetus of
				  not treating opioid use disorder, and the importance of informing medical
				  practitioners of substance use during pregnancy; and
(iv) Family planning.
(e) Create and implement policies and
				  procedures for:
(i) Diversion control that
				  contains specific measures to reduce the possibility of the diversion of
				  controlled substances from legitimate treatment use, and assign specific
				  responsibility to the medical and administrative staff members for carrying out
				  the described diversion control measures and functions;
(ii) Urinalysis and drug testing, to include
				  :
(A) Obtaining specimen samples from each
				  individual, at least eight times within twelve consecutive months;
(B) Documentation indicating the clinical
				  need for additional urinalysis;
(C) Random samples, without notice to the
				  individual;
(D) Samples in a
				  therapeutic manner that minimizes falsification;
(E) Observed samples, when clinically
				  appropriate; and
(F) Samples
				  handled through proper chain of custody techniques.
(iii) Laboratory testing;
(iv) The response to medical and psychiatric
				  emergencies; and
(v) Verifying the
				  identity of an individual receiving treatment services, including maintaining a
				  file in the dispensary with a photograph of the individual and updating the
				  photographs when the individual's physical appearance changes
				  significantly.